Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 0.60 |
| ▸ | FNTB | P49356 | 7/20 | 0.60 |
| ▸ | BAZ2B | Q9UIF8 | 5/20 | 0.56 |
| ▸ | BAZ2A | Q9UIF9 | 5/20 | 0.56 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.51 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.51 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18556097 | 0.88 | FNTA (0.54) | FNTAFNTBBAZ2BBAZ2ABRD9 | |
| SCHEMBL24510742 | 0.87 | BAZ2B (0.55) | FNTAFNTBBAZ2BBAZ2ABRD9 | |
| SCHEMBL24510741 | 0.81 | BAZ2B (0.57) | FNTAFNTBBAZ2BBAZ2ABRD9 | |
| SCHEMBL18555942 | 0.77 | BAZ2B (0.47) | FNTAFNTBBAZ2BBAZ2ABRD9 | |
| SCHEMBL9531095 | 0.75 | FNTA (0.69) | FNTAFNTBBAZ2BBAZ2ABRD9 | |
| SCHEMBL26129098 | 0.73 | NOTUM (0.47) | FNTAFNTBKDM4EALDH1A1HPGD | |
| SCHEMBL343192 | 0.71 | FNTA (0.44) | FNTAFNTBBAZ2BBAZ2ABRD9 | |
| SCHEMBL24510745 | 0.71 | BAZ2B (1.00) | BAZ2BBAZ2ABRD9SMARCA2SMARCA4 | |
| SCHEMBL23318447 | 0.71 | BAZ2B (0.65) | BAZ2BBAZ2ABRD9SMARCA2SMARCA4 | |
| SCHEMBL18555699 | 0.70 | ALDH1A1 (0.50) | BAZ2BBAZ2ABRD9SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| CN-117279636-A | Methods and compounds for modulating myotonic muscular dystrophy type 1 | 设计治疗公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-111320621-B | Indolizine compound and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-113248499-A | Preparation and application of indolizine compound | 中国科学院广州生物医药与健康研究院 | 2021-08-13 | — | — | CN | disclosed |
| CN-111320621-A | Indolizine compound and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2020-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | FNTA 3860/4885FNTB 2738/4885BAZ2B 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.